Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial.
Chong WQ, Low JL, Tay JK, Le TBU, Goh GS, Sooi K, Teo HL, Cheo SW, Wong RT, Samol J, Lim MY, Li H, Shirgaonkar N, Chia S, Wang L, Gopinathan A, Eu DK, Tsang RK, Loh KS, Toh HC, Syn N, Kong LR, Dasgupta R, Tai BC, Lim YC, Goh BC.
Chong WQ, et al. Among authors: low jl.
Lancet Oncol. 2025 Jan 15:S1470-2045(24)00677-6. doi: 10.1016/S1470-2045(24)00677-6. Online ahead of print.
Lancet Oncol. 2025.
PMID: 39826567